Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ACC Meeting ENHANCE Panel Calls For Return To Statins

This article was originally published in The Pink Sheet Daily

Executive Summary

The failed atherosclerosis study provides “no new evidence to support the use of this drug,” a cardiology panel says.

You may also be interested in...



ACCORD, ADVANCE Kick Off ADA’s Day One

Data show cutting glucose levels to near-normal levels may help diabetics dodge kidney disease.

ACCORD, ADVANCE Kick Off ADA’s Day One

Data show cutting glucose levels to near-normal levels may help diabetics dodge kidney disease.

Merck Revises Guidance To Include $700 Million Less In Vytorin/Zetia Sales

Company, however, reaffirms EPS guidance for the year.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS067503

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel